Quick Answer
Aspire Biopharma Holdings, Inc. reported Net Income of -$24.48 million for fiscal year 2025.
Aspire Biopharma Holdings, Inc. — Key Financials by Year
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Net Income | -$24.48M -1768.9% |
-$1.31M -129.3% |
$4.46M +33.6% |
$3.34M +13211.8% |
-$25.5K |
| Diluted EPS | -$16.38 -762.1% |
-$1.90 | — | — | — |
| Total Assets | $1.31M +786.7% |
$148.0K -99.3% |
$19.98M -93.3% |
$300.18M +102274.0% |
$293.2K |
| Stockholders Equity | -$6.38M -314.0% |
-$1.54M -215.7% |
-$487.9K +95.1% |
-$9.94M | $0.00 |
| R&D Expense | $923.9K +540.0% |
$144.4K | — | — | — |
| Operating Income | -$19.35M -1498.1% |
-$1.21M | — | — | — |
| Gross Profit | -$116.00 | — | — | — | — |
| Shares Outstanding | 3.53M +412.1% |
690,044 | — | — | — |
Most Recent Quarter
| Metric | Quarter Ending | Value | YoY | QoQ |
|---|---|---|---|---|
| Net Income | September 30, 2025 | -$1.85M | -755.6% | +6.6% |
| Diluted EPS | September 30, 2025 | -$0.04 | -300.0% | -300.0% |
| Total Assets | September 30, 2025 | $2.40M | -63.9% | +142.9% |
| Stockholders Equity | September 30, 2025 | -$11.47M | -1380.8% | -19.2% |
| R&D Expense | September 30, 2025 | $207.9K | +2870.0% | -41.1% |
| Operating Income | September 30, 2025 | -$1.15M | -432.2% | -432.2% |
| Gross Profit | September 30, 2025 | $884.00 | — | — |
| Shares Outstanding | September 30, 2025 | 49.53M | — | +0.0% |
- Aspire Biopharma Holdings, Inc. reported Net Income of -$24.48 million for fiscal year 2025.
- Aspire Biopharma Holdings, Inc. showed a decrease of -1768.9% in Net Income compared to the prior fiscal year.
- Aspire Biopharma Holdings, Inc. reported Diluted EPS of $16.38 per share (loss) for fiscal year 2025.
- Aspire Biopharma Holdings, Inc. showed a decrease of -762.1% in Diluted EPS compared to the prior fiscal year.
- Aspire Biopharma Holdings, Inc. reported Total Assets of $1.31 million for fiscal year 2025.
- Aspire Biopharma Holdings, Inc. showed an increase of +786.7% in Total Assets compared to the prior fiscal year.
- Aspire Biopharma Holdings, Inc. reported Stockholders Equity of -$6.38 million for fiscal year 2025.
- Aspire Biopharma Holdings, Inc. showed a decrease of -314.0% in Stockholders Equity compared to the prior fiscal year.
- Aspire Biopharma Holdings, Inc. reported R&D Expense of $923.9 thousand for fiscal year 2025.
- Aspire Biopharma Holdings, Inc. showed an increase of +540.0% in R&D Expense compared to the prior fiscal year.
- Aspire Biopharma Holdings, Inc. reported Operating Income of -$19.35 million for fiscal year 2025.
- Aspire Biopharma Holdings, Inc. showed a decrease of -1498.1% in Operating Income compared to the prior fiscal year.
- Aspire Biopharma Holdings, Inc. reported Gross Profit of -$116.00 for fiscal year 2025.
- Aspire Biopharma Holdings, Inc. reported Shares Outstanding of 3.53 million shares for fiscal year 2025.
- Aspire Biopharma Holdings, Inc. showed an increase of +412.1% in Shares Outstanding compared to the prior fiscal year.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: